argenx SE (NASDAQ:ARGX) Receives Consensus Rating of “Moderate Buy” from Analysts

Shares of argenx SE (NASDAQ:ARGX – Get Rating) have been given an average recommendation of “Moderate Buy” by the seventeen ratings firms that are currently covering the stock, Marketbeat reports. One equities research analyst has rated the stock with a hold rating and fourteen have assigned a buy rating to the company. The average 1-year price objective among brokerages that have updated their coverage on the stock in the last year is $454.08.

Several research firms have issued reports on ARGX. SVB Leerink raised their target price on argenx from $430.00 to $435.00 and gave the stock an “outperform” rating in a research note on Friday, March 3rd. JPMorgan Chase & Co. upped their price target on argenx from €470.00 ($505.38) to €480.00 ($516.13) and gave the stock an “overweight” rating in a research note on Monday, November 14th. SVB Securities lifted their price objective on argenx from $430.00 to $435.00 in a research note on Friday, March 3rd. William Blair started coverage on argenx in a report on Tuesday, December 6th. They issued an “outperform” rating on the stock. Finally, HC Wainwright restated a “buy” rating and set a $480.00 target price on shares of argenx in a report on Friday, March 3rd.

Institutional Investors Weigh In On argenx

Several hedge funds have recently modified their holdings of the stock. Price T Rowe Associates Inc. MD lifted its position in shares of argenx by 3.0% in the 2nd quarter. Price T Rowe Associates Inc. MD now owns 6,377,316 shares of the company’s stock worth $2,416,237,000 after buying an additional 182,835 shares during the last quarter. FMR LLC boosted its stake in argenx by 6.3% in the second quarter. FMR LLC now owns 4,974,343 shares of the company’s stock valued at $1,884,680,000 after acquiring an additional 294,228 shares during the period. BlackRock Inc. grew its holdings in shares of argenx by 2.3% during the third quarter. BlackRock Inc. now owns 804,719 shares of the company’s stock valued at $284,106,000 after purchasing an additional 18,092 shares during the last quarter. Capital World Investors raised its position in shares of argenx by 12.0% during the 1st quarter. Capital World Investors now owns 739,392 shares of the company’s stock worth $233,138,000 after purchasing an additional 79,119 shares during the period. Finally, Morgan Stanley raised its position in shares of argenx by 236.9% during the 4th quarter. Morgan Stanley now owns 630,330 shares of the company’s stock worth $238,788,000 after purchasing an additional 443,217 shares during the period. 57.29% of the stock is currently owned by hedge funds and other institutional investors.

argenx Stock Performance

NASDAQ:ARGX opened at $352.64 on Tuesday. The stock has a market capitalization of $19.56 billion, a PE ratio of -26.86 and a beta of 0.74. argenx has a fifty-two week low of $267.35 and a fifty-two week high of $407.93. The company has a fifty day moving average of $373.39 and a two-hundred day moving average of $373.55.

About argenx

(Get Rating)

argenx SE operates as a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases. It operates from the Netherlands, Belgium, the United States of America, Japan, Switzerland, Germany and France. The firm partnering with academic researchers through its Immunology Innovation Program (IIP), argenx aims to translate immunology breakthroughs into a world-class portfolio of novel antibody-based medicines.